Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study

BACKGROUND: Palbociclib was the only available cyclin‐dependent kinase 4/6 inhibitor in China until very recently, and its effect has not been systemically evaluated among Chinese patients. This study aims to assess the efficacy, safety and patient‐reported outcomes (PROs) of palbociclib plus endocr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Lesang, Zhou, Jun, Chen, Yiding, Ding, Jinhua, Wei, Haiyan, Liu, Jian, Xia, Wenjie, Xie, Bojian, Xie, Xiaohong, Li, Xujun, Dai, Yuechu, Zhang, Guobing, Qiu, Xia, Li, Chao, Sun, Shanshan, Chen, Wuzhen, Gong, Dihe, Li, Hengyu, Huang, Jian, Jiang, Xia, Ni, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678098/
https://www.ncbi.nlm.nih.gov/pubmed/35470572
http://dx.doi.org/10.1002/cam4.4767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678098/
https://www.ncbi.nlm.nih.gov/pubmed/35470572
http://dx.doi.org/10.1002/cam4.4767

Ejemplares similares